论文部分内容阅读
用双抗体夹心ＥＬＩＳＡ法检测了３９例原发性中晚期肝癌患者栓塞化疗前后和２０例正常人血清ｓＩＬ－２Ｒ水平。结果表明：肝癌患者栓塞化疗前血清ｓＩＬ－２Ｒ水平显著地高于对照组，栓塞化疗后ｓＩＬ－２Ｒ水平显著地低于治疗前。以对照组血清ｓＩＬ－２Ｒ均数与两倍标准差之值为标准，肝癌患者和对照组的异常阳性率分别为７１．８０％和１０％。研究结果提示：检测ｓｌＬ－２Ｒ与常用的ＡＦＰ血清学检测方法对肝癌诊断具有互补作用，栓塞化疗后病人血清ｓＩＬ－２Ｒ水平对判断疗效和预后具有重要意义。
The levels of serum sIL-2R in 39 patients with primary and advanced hepatocellular carcinoma before and after embolization chemotherapy and 20 normal controls were detected by double antibody sandwich ELISA. The results showed that serum sIL-2R levels were significantly higher in patients with hepatocellular carcinoma before embolization chemotherapy than in the control group. The level of sIL-2R after embolization chemotherapy was significantly lower than before treatment. The mean of sIL-2R in the control group and the standard deviation of the standard were two times. The abnormal positive rates of the liver cancer patients and the control group were 71.80% and 10%, respectively. The results suggest that the detection of slL-2R and commonly used AFP serological assays have a complementary effect on the diagnosis of HCC. The level of serum sIL-2R after embolization chemotherapy has important significance in judging the efficacy and prognosis.